Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02126553 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT02126553: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02126553 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02126553, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This phase II trial studies how well lenalidomide works in treating patients with acute myeloid leukemia that have had a decrease in or disappearance of signs and symptoms of cancer, although cancer still may be in the body and may be likely to come back or spread. Biological therapies, such as lenalidomide, use substances made from living organisms that may kill cancer cells by blocking blood flow to the cancer and by stimulating white blood cells to kill the cancer cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-11-13 |
| Est. Completion | 2021-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02126553
The ClinicalTrials.gov registry entry for NCT02126553 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02126553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02126553 about?
NCT02126553 is a clinical study titled "Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission". This phase II trial studies how well lenalidomide works in treating patients with acute myeloid leukemia that have had a decrease in or disappearance of signs and symptoms of cancer, although cancer still may be in the body and may be likely to come back or spread. Biological therapies, such as lena...
What is the current status of trial NCT02126553?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2014-11-13. Estimated completion is 2021-11-30.
What interventions are being tested in trial NCT02126553?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT02126553?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.